Table IV.
Safety and efficacy of selected studies
| Study | Study times | Pain vs control | Functional vs control | Other | Adverse event with mesotherapy | Serious adverse event with mesotherapy |
|---|---|---|---|---|---|---|
| Costantino et al. 2011 (26) | AT 6 months |
VASb VASb |
b
b |
– | Transient bleeding and signs of inflammation in some patients resolved in few days | None |
| Saad et al., 2019 (33) |
AT 3 months |
VASa* VASa* |
ROMb ODQb ROMb ODQb |
/ | None | None |
| Kocak 2019 (34) | 10-20 min 60-120 min 1 week |
VASa* VASa* VASa* |
/ | – | None | None |
| Monticone et al., 2004 (35) | AT 6 months 12 months |
VASa* VASa* VASa* |
/ | Laslett's test and Mens's testnegative Laslett's test and Mens's testnegative Laslett's test and Mens's testnegative |
None | None |
| Moretti et al., 2005 (36) |
AT | [Shoulder] VAS:a* [Wrist, hand, elbow, knee] VASb [Pubic] VAS:a [Foot] VASa |
No. patients with adverse drug reaction7/40 (17.5%) [pain in the site of injection, allergic reaction, recurrence of pain] | None | ||
| Saggini et al., 2015 (37) |
AT 30 days 90 days |
VASb VASb VASb |
KOOSb KOOSb KOOSb |
UltrasonographyC | Not available | Not available |
| Senara et al., 2015 (38) |
AT 6 months |
VASa* VASa* |
RMDQC* RMDQC* |
/ | Not available | Not available |
| Yang et al., 2018 (39) | 3 h 1 days 3 days |
VASa* VASa* VASa* |
NDIC* PGICC* NDIC* PGICC* NDIC* PGICC* |
/ | No. patients with adverse drug reaction 2/18 (11.1%) [Fatigue] 2/18 (11.1%) [Dizziness] 2/18 (11.1%) [Bruising] |
None |
a
Decrease value or increase value vs control.
b
Similar outcome in experimental vs control.
C
Improvement or worsening value versus control
*
Statistically significant differences.
AT: after treatment; h: hours; KOOS: Knee Injury and Osteoarthritis Outcome Score; min: minutes; NDI: Neck Disability Index; ODQ: Oswestry Low Back Pain Disability Questionnaire; PGIC: Patient Global Impression of Change; RMDQ: Roland Morris Disability Questionnaire; ROM: range of movement; VAS: visual analogue scale.